As part of this collaboration, EUROAPI will develop and industrialize the manufacturing process of innovative cosmetic ingredients through its Contract Development and Manufacturing Organization (CDMO) activity. This agreement encompasses several projects, the first of which will take place at EUROAPI’s Frankfurt site with a dedicated line of complex chemistry production.

"Cosmetics is a new and growing segment for EUROAPI’s CDMO business. Signing this manufacturing agreement with Novéal demonstrates our ability to adapt to cosmetics’ short timelines and regulatory and quality requirements," said Cécile Maupas, Chief CDMO Officer of EUROAPI. "This multi-million-euro contract is a strong recognition of EUROAPI’s broad panel of technologies and capacities to respond to the increasing demand across different modalities, and to guarantee full business continuity for cosmetic ingredients."

The CDMO activity is a strategic priority for EUROAPI. Since the creation of its dedicated CDMO business development team in 2021, EUROAPI has achieved substantial results and doubled the number of customers in only one year, with 79 projects won from preclinical phase up to commercial supply.

About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries.